A985G Polymorphism of the Endothelin-2 Gene and Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy

Clinical Impact of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy Results From Kochi RYOMA Study

“…As for the subtypes of HCM, 40 patients (15%) showed LV outflow obstruction (pressure gradient ≥30 mmHg at rest), a prevalence that was lower than that in cohorts in Western countries. [7][8][9][10]19 Clinical Impact of AF The reported prevalence of AF in several HCM populations has been approximately 20%, 1,8,12,17,20 whereas in the present study it was 28% and probably related to the aged cohort. In fact, the prevalence of AF increased with age.…”

Exercise capacity and paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy

“…Genetic susceptibilities, for example, may concurrently increase the risk of exercise intolerance and AF. Potential mechanisms include the induction of characteristic patterns of ventricular remodelling,23 24 atrial enlargement23 and systemic vasodilation or reduction in intravascular volume predisposing patients to hypotension and increased adrenergic tone 25 26. Additional studies are necessary to assess which mechanisms that underlie exercise intolerance may also increase the propensity for AF.…”

Implication of Endothelin-2 and Oxidative Stress Biomarkers in Essential Hypertension

“…In this context various clinical trials using endothelin antagonists have demonstrated potentially beneficial effects in patients with essential hypertension, pulmonary hypertension and heart failure [34]. Various studies have demonstrated that the ET-2 gene polymorphism (A985G) is significantly associated with increased incidence of atrial fibrillation [35][36][37][38]. Overall evidence from all these studies suggests that ET-2 may also modulate vascular tone like ET-1 and exert control on vascular tissue morphology and remodelling.…”